Attana participates at the Stora Aktiedagen Göteborg 2019
Attana will participate at ”Stora Aktiedagen Göteborg 2019” on Monday November 4th. The CEO of Attana, Teodor Aastrup, will present how the company has assisted customers with their drug development.
The presentation will focus on the benefits that Attana provides customers with:
- Determination of affinity and kinetics: from simple to complex interactions
- Off-target analysis: cells, tissues and sera
- Target validation under biologically relevant conditions
- Selection and optimisations based on detailed interaction characterisation with cells, tissues and in sera
- Analysis of sera for rapid understanding of immune response
In summary, Attana provides customers with an improved possibility to predict a new drug’s in vivo performance. Two examples will be given in the presentation:
GeNeuro whose antibody Temelimab (with project namt GNbAC1) has passed Phase 1 and is currently in Phase 2 studies.
Prof. Roland Kontermann at University of Stuttgart, who has developed the antibody ATROSIMAB and is planning to initiate Phase 1 studies at the beginning of 2021.
On Attana’s homepage publications of these antibodies are listed.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact email@example.com.